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Mistletoe extracts are used as alternative cancer treatment in addition to standard chemotherapy and radiation treatment and have
an immunostimulatory and pain-relieving effect. A direct antitumour effect of mistletoe extracts against tumour cells of lymphoid
origin has been linked to the D-galactoside-specific mistletoe lectin I. In this study, we investigated the cellular effect of bacterially
expressed, recombinant mistletoe lectin alone or in combination with ionising radiation in a genetically defined p53-wild-type and
p53-deficient E1A/ras-transformed murine tumour cells system. Downregulation of the proliferative activity and cell killing by
recombinant mistletoe lectin occurred in a clear dose response (0.1–1ngml
 1). Induction of apoptosis was p53-independent, but
apoptosis-associated factor-1-dependent. Cellular treatment with lectin in combination with ionising radiation resulted in both p53-
wild-type and p53-deficient tumour cells in an at least additive, antiproliferative effect and enhanced activation of caspase-3.
Combined treatment with ionising radiation and lectin revealed a similar cytotoxic effect in human, p53-mutated adenocarcinoma
cells. Thus, recombinant mistletoe lectin alone and in combination with ionising radiation bypasses often prevalent apoptotic
deficiencies in treatment-resistant tumour cells.
British Journal of Cancer (2003) 88, 1785–1792. doi:10.1038/sj.bjc.6600982 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: mistletoe lectin; apoptosis; p53; Apaf-1; ionising radiation
                                            
Mistletoe extracts are often used as complementary cancer
treatment in addition to standard chemotherapy and radiation
treatment and are reported to have an immunostimulatory and
pain-relieving effect (Hajto et al, 1989; Beuth et al, 1992; Heiny
et al, 1998; Stein and Berg, 1998; Ernst and Cassileth, 1999). A
direct antitumour effect of mistletoe has been linked to the specific
components lectin I–III that can induce apoptosis in various
transformed cell lines, in particular in tumour cells of lymphoid
origin. (Janssen et al, 1993; Bu ¨ssing et al, 1996; Hostanska et al,
1996; Bantel et al, 1999). The main effector in mistletoe extracts
presumably is the D-galactoside-specific mistletoe lectin I (ML-I).
Mistletoe lectin-I is a heterodimer that consists of the toxic
A-chain, a site-specific type II ribosome-inactivating N-glycosi-
dase, and the carbohydrate-binding-subunit B responsible for
cellular lectin uptake (Endo et al, 1988; Eck et al, 1999a,b).
Depending on the stimulus that initiates apoptosis, specific
proteolytic caspase cascades, the core of the apoptotic programme,
are activated. While death-ligand-mediated receptor activation
facilitates the clustering and autoprocessing of caspases (initiator
caspase-8) at the plasma membrane, other stress stimuli activate
caspases at intracellular sites (Tepper et al, 1999). Mitochondrial
cytochrome c is released into the cytosol upon cellular stress,
where in the presence of ATP/dATP it associates with the
apoptosis-associated factor 1 (Apaf-1) and procaspase-9 to process
the protease to its active form (Liu et al, 1996; Li et al, 1997; Sun
et al, 1999). This complex activates the effector caspase-3 leading
to the observed cellular apoptotic morphology. Recently, induction
of apoptosis in Jurkat leukemic T cells by ML-I was linked to
activation of caspase-8 but independent of death receptor
signalling (Bantel et al, 1999).
The state of the tumour suppressor p53 is pivotal for the
response of tumour cells to chemo- and radiotherapy. Mutations in
the p53 gene are involved in acquired and intrinsic treatment
resistance in human tumours and render tumour cells refractory to
many anticancer therapies (Lowe et al, 1994; Hainaut et al, 1998).
Following irradiation, p53 is activated and induces a crucial block
to cell cycle progression providing enough time for sufficient
DNA-repair prior to deleterious DNA-replication in Sphase. On
the other hand, apoptosis may arise through p53-mediated signal
transduction cascades leading to the activation of the apoptotic
machinery. Various p53-inducible genes are known, although the
specific apoptotic signalling network induced by p53 is only now
emerging (Giaccia and Kastan, 1998; Soengas et al, 1999; Schuler
et al, 2000). Thus, chemotherapeutic agents that alone or in
combination with additional treatment modalities bypass the p53-
dependent death pathway and induce p53-independent cell killing
are interesting compounds for cancer treatment.
In this study, we investigated the cytotoxic effect and mechan-
ism of cell death of recombinant ML alone or in combination with
ionising radiation (IR) in a genetically defined p53-wild-type and
p53-deficient tumour cell system and in cells lacking an intact
Apaf-1/caspase-apoptotic pathway. This murine E1A/ras-trans-
formed cell system has previously been described for its strict
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sp53- or Apaf-1-dependent apoptotic response to treatment with IR
and different cytotoxic drugs in vitro and in vivo (Lowe et al,1 9 9 3 a ;
Soengas et al,1 9 9 9 ;Z a u g get al, 2001). Furthermore, the response to
combined treatment has also been investigated in the human p53-
mutated and IR-resistant colon adenocarcinoma cell line SW480.
MATERIALS AND METHODS
Recombinant ML and cell cultures
Recombinant ML (rML, rViscumin) was kindly provided by
H Zinke (VISCUM GmbH, Zwingenberg, Germany). rML (Mr
55kDa) was produced by cloning and separate expression of the
two subunits A and B in Escherichia coli and renatured in a
coassociation process (Eck et al, 1999a). E1A/T24 H-ras-trans-
formed mouse embryo fibroblasts (MEFs) were cultured as
described (Lowe et al, 1993b; Rocha et al, 2000). Unclonal mass
cultures of E1A/ras-transformed Apaf-1-wild-type and deficient
cells were prepared as previously described (Soengas et al, 1999)
and cultured in Dulbecco’s modified Eagle’s medium 10% foetal
calf serum (FCS), supplemented with penicillin and streptomycin.
The human adenocarcinoma cell line SW480 was cultured in
RPMI-1640-media supplemented with 10% FCS.
Cell proliferation assay, trypan blue exclusion assay
and irradiation
Treatment with rML was performed in presence of 2% FCS for 4h
followed by serum addition to 20% final serum concentration. For
Annexin V-, Dcm- and PI-exclusion-experiments (see below), the
serum concentration was not readjusted. Control experiments were
performed with the corresponding serum conditions. Tumour cell
proliferation was assessed by the colorimetric alamar blue assay, a
proliferation assay that assesses metabolic activity comparable to
the MTT-tetrazolium-based [3-(4,5-dimethylthiazol-2-yl)2,5-di-
phenyltetrazolium bromide] quantification assay of cell metabo-
lism (Biosource International, Camarillo, CA, USA). All proliferation
experiments (in triplicate) were repeated as independent experi-
ments at least twice. For trypan blue exclusion floating and adherent
cells were collected, diluted 1:1 with 0.4% trypan blue solution
(Sigma, Buchs, Switzerland) and scored under a light microscope.
The results represent the meanþs.d. of two independent
experiments, with a minimum of 100 cells scored per treatment.
Irradiation of cell cultures was carried out at room temperature in
tissue culture dishes (100 100mm) with a 6MV linear accelerator
at a dose rate of 2Gymin
 1 or in 96-well plates using a Pantak
Therapax 300kV X-ray unit at 0.7Gymin
 1 and was always
applied 1h following rML treatment.
Analysis of cell viability, apoptotic nuclei, and Annexin
V-binding by flow cytometry
Plasma membrane integrity was analysed by live–dead discrimi-
nation after staining with propidium iodide (PI, Sigma) at a final
concentration of 5mgml
 1 for 15min (Hostanska et al, 1996). The
DNA content in treated cells was analysed by flow cytometry after
staining in hypotonic fluorochrome solution (Nicoletti et al, 1991;
Hostanska et al, 1996). Apoptotic cells were detected and
quantified by staining with Annexin V-FITC (Roche Diagnostics,
Rotkreuz, Switzerland) (Vermes et al, 1995) with a FACSCalibur
flow cytometer (Becton Dickinson, Mountain View, CA, USA). The
FACS histograms were analysed using CellQuest acquisition and
analysis software.
Mitochondrial transmembrane potential Dwm
Cells (2 10
4 per ml) were incubated with the cationic dye JC-1
(1mM, 5,50, 6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolocarbo-
cyanine iodide, Molecular Probes, Eugene, USA) for 5min at 371C
and analysed by flow cytometry (Zamzami et al, 1995). Changes
from red (JC-1 aggregate) to green fluorescence (monomer)
resulting from membrane depolarisation were evaluated on
histograms. Statistical analysis of histograms was calculated using
the Kolmogorov–Smirnov (K–S) two-sample test for overlaid
histograms.
Preparation of cytosolic cell fraction and Western blotting
Treatment with rML was performed in the presence of 2% FCS for
4h followed by serum addition to 20% final serum concentration.
Trypsin-treated cells were harvested and the cytosolic cell fraction
was prepared as described previously (Rocha et al, 2000). Proteins
were resolved by sodium dodecyl sulphate–polyacrylamide elec-
trophoresis and Western blotting was performed with the primary
rabbit polyclonal anti-cleaved caspase-3 antibody (New England
Biolabs, Beverly, MA) and antibody detection was achieved by ECL-
enhanced chemiluminescence (Amersham, Cardiff, UK) using a
horseradish peroxidase-conjugated secondary antibody.
RESULTS
Cytotoxic effect of rML is p53-independent
The effect of rML on tumour cell proliferation was tested in E1A/
ras-transformed p53-wild-type (þ/þ) and p53-deficient ( / )
murine embryo fibroblasts. This tumour cell system was
previously described for its strict p53-dependent response to
treatment with IR and different cytotoxic drugs in vitro and in vivo
(Lowe et al, 1994; Pruschy et al, 1999; Rocha et al, 2000; Zaugg et al,
2001). To assess a p53-dependent stress response with these cells,
initial control experiments were performed to determine the
proliferative activity 48h after serum withdrawal. When compared
to the proliferative activity of cells growing in complete serum-
supplemented medium, the proliferative activity of the p53-wild-
type and p53-deficient cell population in the absence of serum
were reduced to 2 and 39%, respectively, showing a clear p53-
dependent stress response (data not shown). Treatment with
increasing doses of rML (0–0.5ngml
 1) drastically reduced the
proliferative activity of both p53-wild-type and p53-deficient
transformed cell populations. The proliferative activity was
reduced in both cell populations in a clear dose response as tested
over a 72h time period after treatment (Figure 1A, B). Treatment
with higher doses of rML (1ngml
 1) completely abrogated the
metabolic activity (not shown). In parallel, the cytotoxic effect of
rML-treatment in p53þ/þ and p53 /  transformed cells was
determined 24h after treatment by PI exclusion. No significant
difference in cell survival between these two cell lines was observed
when cells were treated with increasing concentrations of rML
(Figure 1C). Thus, the strongly reduced proliferative activity in the
two cell populations by rML is most probably due to cell killing by
rML, and these results indicate that rML induces its cytotoxic effect
in a p53-independent way.
Next, the mode of cell death induced by rML-treatment was
determined by Annexin V staining. As part of an apoptotic
process, asymmetrically distributed plasma membrane phospho-
lipids, for example, phosphatidylserine, become exposed on the
outer cell membrane layer and this process can be assessed by
Annexin V binding. Control experiments were performed to
compare the response to rML with a strict p53-dependent
induction of apoptosis (serum withdrawal) in these oncogene
transformed cells. A large shift of Annexin V-binding-positive cells
was detected 24h after serum withdrawal in the p53þ/þ but not
in the p53 /  cell population (Figure 2A, B; 77 vs 6% Annexin V-
positive cells). Treatment with increasing concentrations of rML
induced a dose- and time-dependent increase of Annexin
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sV-positive staining cells. After treatment with 0.1ngml
 1 rML for
4h 10 and 3%, and after 24h 63 and 29% of the p53þ/þ and
p53 /  cells, respectively, stained Annexin V positive. Treatment
with an increased concentration of rML (1ngml
 1) for 4h resulted
in 41 and 36% Annexin V-positive cells, and after 24h 94 and 68%
of the p53þ/þ and p53 /  cells stained Annexin V positive
(Figure 2C, D). In parallel, the DNA content in treated cells was
analysed by flow cytometry. The apoptotic cells show a diminished
DNA staining that can be traced below the G0/G1 population. A
distinct hypodiploid (sub-G1) cell population was observed after
treatment with increasing rML-doses. No significant differences
in the amount of p53þ/þ and p53 /  cells with apoptotic
nuclei was observed 24h after incubation with 0.1ngml
 1 (37 and
26%, respectively) and 1ngml
 1 rML (72 and 66%, respectively)
(Figure 2E, F). These results indicate a predominantly p53-
independent mechanism of apoptosis induction by rML.
A hallmark for apoptosis is loss or reduction of the mitochon-
drial membrane potential (DCm). To investigate a change of DCm
on rML-treatment, p53þ/þ and p53 /  cells were incubated
for 6h with 0.5ngml
 1 rML. As a positive control experiment, cells
were treated for 15min with the K
þ-ionophore valinomycin
(50nM) or for 3h with staurosporine (1mM), which was previously
shown to act as a p53-independent inducer of apoptosis (Rocha
et al, 2000). 5,50,6,60-tetrachloro-1,10,3,30-tetraethyl-benzamida-
zolocarbocyanin iodide (JC-1) is incorporated into mitochondria
forming aggregates (red fluorescence) and monomers (green
fluorescence), and mitochondrial depolarisation is indicated by a
decrease in the ratio of red to green fluorescence. The ratio of red/
green fluorescence in the untreated cell populations was 5.1 for the
p53þ/þ and 5.2 for the p53 /  cell population, respectively. As
expected a complete loss of DCm occurred in both cell population
upon addition of the uncoupler valinomycin (ratio 0.008). Likewise
treatment of p53þ/þ and p53 /  transformed cells with
staurosporine and rML reduced DCm to a large extent in both
cell population. Treatment with rML (0.5ngml
 1) reduced the red/
green-fluorescence ratio to 0.08 for the p53þ/þ and to 0.22 for
the p53 /  cell population showing p53-independent mitochon-
drial depolarisation by rML (Figure 3). The corresponding ratio
values after staurosporine-treatment were 0.62 and 1.24, respec-
tively. Thus, mitochondrial depolarisation by staurosporine and
rML correlate with their p53-independent cytotoxic activity.
Overall, these results obtained with a genetically defined tumour
cell system indicate that the antiproliferative and cytotoxic effect of
recombinant ML is due to p53-independent induction of apoptosis
by rML.
Apoptosis-associated factor-1-dependent induction of
apoptosis by rML
To further explore the mechanism of rML-induced apoptosis,
formation of caspase-3 was analysed in E1A/ras-transformed MEFs
derived from Apaf-1-wild-type and Apaf-1-deficient mice. Apop-
tosis-associated factor-1 is an important cofactor for the assembly
of the apoptosome complex that is required for activation of the
initiator-caspase-9 and subsequent activation of caspase-3 as part
of the cytochrome c-mediated caspase-9/-3 apoptotic pathway. The
cytotoxic effect of increasing concentrations with rML
(0–0.5ngml
 1) was determined in Apaf-1þ/þ and Apaf-1 / 
E1A/ras-transformed MEFs. Quantitative analysis of dead cells was
performed with the trypan blue exclusion assay. A dose-dependent
increase of cell killing was observed in wild-type E1A/ras-
transformed MEFs, while Apaf-1-deficient cells were strongly
resistant to rML-treatment (77 vs 20% cell death at 0.5ngml
 1
rML) (Figure 4A). In parallel, cellular lysates derived from rML-
treated E1A/ras-transformed Apaf-1þ/þ and Apaf-1 /  cells
were probed for active caspase-3-formation with the caspase-3-
specific antibody. Interestingly, caspase-3-formation could only be
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Figure 1 p53-independent antiproliferative and cytotoxic effect of rML.
E1A/ras-transformed p53-wild-type (A)a n dp 5 3 - d e f i c i e n t( B)M E F sw e r e
treated with increasing concentrations of rML and proliferative activity was
determined at the indicated timepoints with the alamar blue assay. (C)T h e
cytotoxic effect was determined by PI exclusion 24h after treatment with
increasing concentrations of rML. The small amount of dead cells in p53-wild-
type cells in the absence of treatment might be due to an increased rate of
apoptosis induced by the short incubation time with low serum concentration
( s e eM a t e r i a l sa n dM e t h o d s ) .A b s e n c eo fe r r o rb a r si sd u et om i n i m a ls . d .
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sdetected in the wild type but not in the Apaf-1 /  cells
(Figure 4B). These results indicate that rML requires an intact
cytochrome c/Apaf-1/caspase-9-pathway for apoptosis induction.
Combined effect by rML and irradiation
Mistletoe extracts are often used as complementary cancer
treatment in addition to standard radiation treatment, but the
modulatory effect on treatment response is not clearly resolved.
We tested the antiproliferative effect of combined treatment with
low dose of rML and IR on the p53þ/þ and p53 /  E1A/ras-
transformed MEFs. As previously documented with this cell
system, IR alone reduced the proliferative activity to a larger
extent in the p53þ/þ than in the p53 /  cells. Interestingly,
combined treatment with rML (0.25ngml
 1) and 2Gy induced an
at least additive antiproliferative effect in both cell populations.
Experiments to determine the antiproliferative effect of rML and
IR were also performed against the human p53-mutated adeno-
carcinoma cell line SW480, which has previously shown to be
rather radiation resistant (Hess et al, 2001). Treatment with
increasing doses of rML alone reduced the proliferative activity in
a dose-dependent way and also showed an at least additive effect
when tested in combination with IR (Figure 5A–D). Trypan blue
exclusion performed on SW480 cells corroborated that the lectin
alone has only a partial effect on cell viability, while IR-induced
cell killing was increased in a cooperative way by rML in these cells
(not shown).
Formation of active effector-caspase-3 upon treatment with rML
alone and in combination with IR was determined in cytosolic
lysates derived from the genetically defined p53þ/þ and p53 / 
cells by Western blotting to further understand the combined
effect on the molecular level. A caspase-3-specific antibody was
used that recognises only the cleaved, active form of caspase-3
(Figure 6A, B). Treatment with increasing concentrations of rML
(0, 0.5, 1ngml
 1) activated caspase-3 in both cell population,
supporting p53-independent apoptosis-induction by rML as
observed on the cellular level (see above). When rML-treatment
was combined with IR (2Gy) formation of the active form of
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Figure 2 p53-independent induction of apoptosis by rML. Annexin V-binding was analysed by flow cytometry in E1A/ras-transformed p53-wild-type
(A, C) and p53-deficient (B, D) MEFs 24h after serum withdrawal (A, B, filled histograms) and after treatment with increasing concentrations of rML (C, D;
1: 0ngml
 1 (filled histogram); 2: 0.1ngml
 1; 3: 1ngml
 1). (E, F) Apoptotic loss of DNA-content by flow cytometry of E1A/ras-transformed p53-wild-type
(E) and p53-deficient (F) MEFs 24h after treatment with rML (1: 0ngml
 1; 2: 0.1ngml
 1; 3: 1ngml
 1). The x-axis represents the logarithmic scale of PI
fluorescence intensity of nuclei and the y-axis the number of cells (the percentage of cells in the hypodiploid peak are indicated).
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scaspase-3 was at least additive in both p53þ/þ and p53 /  cell
population, suggesting that the increased antiproliferative effect by
rML in combination with IR is because of enhanced apoptosis-
induction.
DISCUSSION
This report investigates the antiproliferative and cytotoxic effect of
rML alone and in combination with IR in a murine genetically
defined p53þ/þ and p53 /  tumour cell system, which has been
previously used to determine p53-dependent apoptosis induction
(Lowe et al, 1993b, 1994), and in human p53-mutated colon
adenocarcinoma cells. Both p53-wild-type and p53-inactive cell
types were sensitive to increasing concentrations of rML.
Furthermore, mechanistic investigations with the genetically
defined tumour cell system show that breakdown of the
mitochondrial membrane potential and caspase-3-activation oc-
curred in a p53-independent way upon treatment by rML. More
important, the p53-independent, antiproliferative effect by recom-
binant ML well correlated with recombinant ML-induced cell
killing irrespective of the p53-status. Interestingly, p53-indepen-
dent apoptosis-induction was also recently demonstrated in
different tumour cells with a related lectin purified from Korean
mistletoe (Lyu et al, 2002).
Apoptosis was also enhanced in both cell types when rML was
used in combination with IR, which induces apoptosis in a strict
p53-dependent way when applied as single treatment modality.
rML-induced apoptosis, though, was abrogated in cells lacking an
intact cytochrome c-mediated apoptotic pathway, suggesting that
rML acts downstream of p53 but upstream of the apoptotic caspase
machinery.
In tumour cells of lymphoid origin, it was previously demon-
strated that ML-I induces the apoptotic machinery in a cell death-
receptor-independent way and that ML-I and the Korean mistletoe
ML-II activated both initiator caspases-8 and -9 (Bantel et al, 1999;
Kim et al, 2000). Using a genetically defined system for Apaf-1, we
show here that rML-induced apoptosis leading to caspase-3-
activation and rML-mediated cytotoxicity not only activates but
strictly requires this apoptosome-dependent-pathway. In Apaf-1-
deficient E1A/ras-deficient cells, rML-1 did not activate effector
caspase-3 and these cells were resistant to the cytotoxic effect of rML.
Only limited information is present on the initial mechanism of
apoptosis induction by MLs. Mistletoe lectins consist of a toxic
A-chain, the site-specific ribosome-inactivating N-glycosidase, and
a carbohydrate-binding-subunit B. The B-chain is important for
cellular lectin uptake, internalisation of the A-chain and is partially
involved in the induction of cytokine synthesis (Hajto et al, 1990),
but does not induce apoptosis on its own (Hostanska et al, 1996;
Eck et al, 1999b). On the other hand, the cytotoxic and apoptosis-
inducing effect of ML is exerted by the ribosome inactivating
A-chain (Hostanska et al, 1996; Langer et al, 1999). Most probably
it is this protein synthesis-inhibiting subunit that is responsible for
the p53-independent apoptosis-inducing and cytotoxic effect of
rML. Controlled protein synthesis is crucial for the survival of any
cell and the coordinated induction of apoptosis may be linked to
the downregulation of short-lived proteins that are important for
cellular homeostasis and a high apoptotic threshold. The observed
cooperative effect of rML-treatment when used in combination
with IR might be due to the enhancement of this antihomeostatic
response to rML. Combined treatment resulted in an increased
amount of caspase-3-activation in both p53þ/þ and p53 / 
cells indicating that the cooperative IR-effect is not mediated via
p53 either. However, which proteins are immediately affected by
rML alone and in combination with IR and their relation to the
apoptotic machinery is not known so far.
p53-independent interference of gene expression and protein
synthesis resulting in apoptosis is also known for other protein
synthesis inhibitors or cytotoxins such as onconase, and
Pseudomonas exotoxin. Likewise ricin, which also belongs to the
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Figure 3 Loss of mitochondrial membrane potential by rML. The
mitochondrial membrane potential of p53-wild-type and p53 /  deficient
E1A/ras-transformed MEFs was analysed with JC-1 6h after rML-treatment
(0.5ngml
 1). Control experiments were performed with valinomycin
(50nM, 15min) and staurosporine (1mM, 3h). The alterations from JC-1
aggregates (red fluorescence) to JC-1 monomer (green fluorescence) are
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independent experiments.
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Figure 4 Apaf-1-dependent cytotoxicity and caspase-activation by rML-
treatment. (A) Apaf-1-wild-type and Apaf-1-deficient MEFs were treated
with rML (0–0.5ngml
 1) and cell viability was determined by trypan blue
exclusion 24h after treatment. (B) Formation of active caspase-3 was
determined in cytosolic extracts 18h following treatment with rML using a
specific antibody recognising the cleaved caspase-3 subunit.
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sclass of two-chain (type II) ribosome-inactivating proteins,
induces apoptosis in p53-mutated tumour cells (Wu et al, 1993;
Rodriguez et al, 1998). This is in contrast to other stress factors
that also affect the cellular homeostasis such as hypoxia, oncogene
activation or aberrant nucleotide metabolism that induce apopto-
sis although in a p53-dependent way (Giaccia and Kastan, 1998).
The antiproliferative and cytotoxic effect of rML alone and in
combination with IR was prominent both in the murine genetically
defined, oncogene-transformed tumour cell system and in the
human p53-mutated colon adenocarcinoma cell line. Even though
the potential antitumour effect of mistletoe extracts has been
linked to its immunomodulatory mechanism mediated by natural
killer cells, lymphokine-activated killer cells and macrophages, a
cytotoxic effect of purified protein components directed against
tumour cells has been previously reported in vitro and in vivo
(Hajto et al, 1989, 1998; Beuth et al, 1991; Yoon et al, 1995, 1998;
Baxevanis et al, 1998; Schumacher et al, 2000; Elsasser-Beile et al,
2001). The cytotoxic characteristics described for the recombinant
ML in this report will not necessarily predict the cytotoxicity
profile of mistletoe extract or lectins purified from extracts, even
though the immunomodulatory and apoptosis-inducing properties
of the extract correlate with their content of lectins (Haito et al,
1998; Bu ¨ssing and Schietzel, 1999; Hostanska et al, 1999). For
example, minor extract components like viscotoxins, a group of
5kDa polypeptides, might modify the tolerability, specificity and
properties of standardised lectin extracts (Tabiasco et al, 2002).
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Figure 5 Combined antiproliferative effect by treatment with rML and IR. E1A/ras-transformed p53-wild-type (A) and p53-deficient MEFs (B) were
treated with rML (0.25ngml
 1) and IR (2Gy) and the proliferative activity was assessed over 72h after treatment with the MTT-like alamar blue assay.
Irradiation was performed 1h following rML treatment. The antiproliferative effect in the human SW480 cell line was also determined over 72h after
treatment with rML alone (C) or in combination with IR (D). Absence of error bars is due to minimal s.d.
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Figure 6 p53-independent caspase-3-activation upon combined treatment with rML and IR. E1A/ras-transformed p53-wild-type (A) and p53-deficient
(B) MEFs were treated with rML (0, 0.5, 1ngml
 1) alone or in combination with irradiation (2Gy). Irradiation was performed 1h after rML treatment and
formation of active caspase-3 was determined in cytosolic extracts 18h following irradiation using a specific antibody recognising the cleaved caspase-3
subunit.
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sThe biological concept of ML-induced cytotoxicity is intriguing.
This report demonstrates that a recombinant component of
mistletoe extracts overcomes a high apoptotic threshold and
cooperates with IR in tumour cells that lack intact p53 and that are
resistant against classical chemotherapeutics. Thus, it will be
important to identify the specific molecular sensor that triggers
p53-independent induction of the apoptotic machinery by rML.
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